Lee Sung sold $98K of CYTK
Lee Sung (EVP, Chief Financial Officer) sold 1,112 shares of CYTOKINETICS INC (CYTK) at $87.79 on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale details (shares, price, total value) executed under a pre-arranged 10b5-1 plan; this is typically not a standalone fundamental driver.
Market read
Primarily useful for monitoring insider activity; unlikely to materially change valuation expectations by itself.
What to watch
The filing does not disclose intent beyond the plan; without context on prior sales cadence, it’s hard to infer directionality or conviction.
Background
The article is a SEC Form 4 insider transaction disclosure for Cytokinetics, Inc. (CYTK).
Ticker impact
CYTOK CFO Lee Sung filed a Form 4 showing an open-market sale of 1,112 shares at $87.79 on 2026-07-01 under a 10b5-1 plan.
Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.
The filing is a primary-source Form 4, but it is explicitly tied to a pre-arranged 10b5-1 plan and the disclosed size ($~98K) is modest versus typical market-moving thresholds.
Market effects
No sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s near-term risk assessment; traders may watch for follow-on sales or changes in plan behavior.
Key entities
- issuerCYTOKINETICS INC
Company whose CFO insider sale was disclosed on Form 4.
- insiderLee Sung
EVP, Chief Financial Officer; reported an open-market sale under a 10b5-1 plan.
